Tenwise

Executive Summary

Tenwise is an Amsterdam-based startup (founded 2018) at the intersection of AI/ML and genetics/genomics, providing a platform that enhances drug discovery and repurposing workflows. The company leverages text mining on scientific literature to uncover hidden relationships in omics data, improving interpretation and enabling novel hypothesis generation. Additionally, Tenwise assists clients in AI implementation projects for literature review and alternative identification. Despite limited public information on funding or stage, Tenwise addresses a critical bottleneck in drug development—mining vast unstructured data—and operates in the rapidly growing AI-driven biotech space. Its focus on improving efficiency in early-stage research positions it as a potential enabler for pharma companies seeking to accelerate target identification and reduce costs. However, the company remains early-stage with no disclosed revenue or partnerships, presenting both opportunity and risk.

Upcoming Catalysts (preview)

• TBDAnnouncement of first major pharmaceutical partnership35% success
• TBDRelease of upgraded platform with new NLP capabilities50% success
• TBDCompletion of seed funding round40% success